| Name | Title | Contact Details |
|---|
Meditrina, a startup company located in Cupertino, CA, was founded in 2016, and developed the Aveta™ System, a single-use Hysteroscope and Resecting Device, with an all-inclusive HD Visualization and Fluid Management system. A new office Hysteroscopy system which can also be used in the clinic or hospital operating room (OR), for diagnostic or therapeutic Hysteroscopy procedures. Procedures include: Diagnostic Hysteroscopy, biopsy, and soft tissue removal such as, fibroids, polyps, and/or retained products of conception (RPOC).
FORCE Therapeutics is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ACE Surgical Supply Company is a Brockton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The VentriFlo True Pulse Pump is a novel, truly pulsatile blood pumping system designed to achieve superior outcomes, reduce costs and improve safety for pediatric & adult patients who require cardiopulmonary support during surgery or in the ICU.
NeuroOne Medical Technologies Incorporated (Ticker: NMTC) is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, initially targeting epilepsy. Today, our attention is on the development and commercialization of patented thin-film, cortical electrode technology for intracranial electroencephalography (iEEG) and depth electrodes for stereoelectroencephalography (sEEG) recording of brain activity. The products currently available in these categories have significant limitations such as low recording resolution and high risk of infection. NeuroOne believes our technology can address these unmet needs upon initial commercialization with pipeline technology to advance the field by enabling minimally invasive techniques and all-in-one diagnostic and therapeutic options. While our initial focus is Epilepsy, future applications in Parkinson`s disease, Essential tremors, and Dystonia are within sight. NeuroOne technologies will be presented to a well-defined market, eager for the advancement they bring. There are 188 hospital centers licensed to perform epilepsy surgical procedures in the U.S. The current addressable market opportunity for is approximately $525.6 million. As more patients choose the minimally invasive procedures made available by NeuroOne technology, the future opportunity is estimated to be approximately $14.9 billion with full market penetration.